This trial is evaluating whether Elranatamab will improve 1 primary outcome and 14 secondary outcomes in patients with Multiple Myeloma. Measurement will happen over the course of Assessed at every cycles [each cycle approximately 28 days].
This trial requires 76 total participants across 4 different treatment groups
This trial involves 4 different treatments. Elranatamab is the primary treatment being studied. Participants will be divided into 4 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"It was concluded that there is a significant difference between the kappa and beta estimations. The difference between the two estimations is due to the fact that the model used for estimating kappa had higher correlations with the data than the model used for beta. Therefore, we conclude that the estimation of beta has more validity than that of kappa when dealing with plasma cells in bone marrow lesions." - Anonymous Online Contributor
"Results from a recent clinical trial from this study suggest that elranatamab has a therapeutic potential in the treatment of MALT lymphoma. Further studies including larger number of patients and longer duration of follow-up are needed to validate these preliminary findings." - Anonymous Online Contributor
"Neoplasms, plasma cell appear as round or oval masses (see picture) on CT scans. Some neoplasms, plasma cells are MAISs. The combination of CT scan and bone marrow examination helps physicians predict malignancies. Diagnosing neoplasms, plasma cell requires careful and precise histological examination. In the case of neoplasms, plasma cell, careful evaluation of immunohistochemical staining patterns will be helpful in discriminating them from those of benign neoplasms." - Anonymous Online Contributor
"Immunotherapy has been shown to be an effective form of treatment for immunocompetent patients with MM. The recent discovery of PD-1/PD-L1 interaction is likely to have great impact on the development of future MM therapies." - Anonymous Online Contributor
"The most common primary cause of neoplasms was lymphoma (40%) followed by other hematologic malignancies (25%). Other causes included breast carcinoma (3%), lung carcinoma (1%), skin carcinoma (1%), colon carcinoma (1%), and prostate carcinoma (1%). The primary cause of neoplasms varied depending on the type of cancer (lymphoid vs non-lymphoid) and organ system involved." - Anonymous Online Contributor
"Elranatamab combined with Vinca alkaloids was found to be effective in patients with relapsed plasmacytoma. The combination of elranatamab with bortezomib was shown to be effective in patients with relapsed plasmacytoma, who had previously received two chemotherapy regimens." - Anonymous Online Contributor
"Results from a recent paper suggests that elranatamab is ineffective at reducing tumor size in patients with advanced or metastatic MM. Elranatamab should be omitted from further development as an anti-MM agent." - Anonymous Online Contributor
"Elranatamab has shown efficacy and safety in phase II studies for 4 types of cancers, including hematological malignancies, solid tumor metastatic disease, and solid tumors in refractory settings. Elranatamab is currently in ongoing development and clinical trials for many indications." - Anonymous Online Contributor
"Survival rates of all primary neoplasms were higher than those of secondary neoplasms. Survival rates for myeloma and lymphoma were lower than those of brain tumors; the cause was probably related to the high mortality of patients with brain tumors." - Anonymous Online Contributor
"Elranatamab is an anti-CD20 antibody with potent antitumor activity against B-cell malignancies. It was approved by the FDA on January 15, 2019, as a monotherapy for relapsed follicular lymphoma (FL) patients who have received at least two prior systemic therapies. This drug is currently undergoing further development for relapsed and refractory FL, mantle cell lymphoma (MCL), and Waldenström's macroglobulinemia (Waldenström’s) patients who have not received prior therapy." - Anonymous Online Contributor
"The majority of neoplasms (98%) occur in whites; the proportion of blacks was <5%. Neoplasms account for about 1/3 of all outpatient visits to primary care providers. Neoplasms are responsible for about 1/3 of all US deaths attributable to cancer. Neoplasms accounted for nearly 14% of all Medicare payments for ambulatory care in the U.S. annually. There are significant racial differences in neoplasms diagnosed in the U.S. and in the age distributions of neoplasms." - Anonymous Online Contributor